Novabay Pharmaceuticals Inc | Needs refresh | Last updated: 2026-03-29T08:34:16Z
Novabay Pharmaceuticals Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for NVC-422, 0.2% in Urinary Catheter Blockage and Encrustation (Phase 2).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| 0.01% Hypochlorous acid | Viral Conjunctivitis | n/a | Na | Public pipeline row |
| Experimental: CD07223 1.5 % Topical Gel BID | Impetigo | n/a | Phase 2 | Phase 3 | Public pipeline row |
| iLid Cleanser | Sebaceous Gland Diseases | Blepharitis | n/a | Na | Public pipeline row |
| NVC-422, 0.2% | Urinary Catheter Blockage and Encrustation | n/a | Phase 2 | Public pipeline row |
| Auriclosene Solution 0.3% | Bacterial Conjunctivitis | n/a | Phase 2 | Public pipeline row |
| Hypochlorous acid | Surgical Site Infection | n/a | Phase 2 | Public pipeline row |
| Avenova Lid Cleanser | Blepharitis | n/a | Na | Public pipeline row |
| NVC-422 Solution, 0.3% | Adenoviral Conjunctivitis | n/a | Phase 2 | Public pipeline row |
No public catalyst rows matched this view yet.
Estimated cash runway: Runway < 6 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT00692757 | Phase 2 | UNKNOWN | 432 | 2009-01 |
| NCT00781339 | Phase 2 | COMPLETED | 20 | 2010-03 |
| NCT01367314 | Phase 2 | COMPLETED | 129 | 2010-05 |
| NCT01243125 | Phase 2 | COMPLETED | 67 | 2013-07 |
| NCT01670032 | Phase 2 | Phase 3 | COMPLETED | 328 | 2013-08 |
| NCT01532336 | Phase 2 | COMPLETED | 500 | 2014-05 |
| NCT01877694 | Phase 2 | COMPLETED | 217 | 2014-12 |
| NCT02130518 | Phase 2 | UNKNOWN | 140 | 2015-12 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.